The liver’s hepatocytes are the only cells in the entire body that can both store sugar during a meal to prevent hyperglycemia and release sugar during the rest of the day to prevent hypoglycemia. But, hepatocytes will only function in this way if they receive insulin in the right amount at the right time. This is extremely difficult to achieve when insulin is injected under the skin because of the tendency of subcutaneous insulin to be taken up by muscle and fat cells before reaching the liver.
HDV is a globally-patented, Phase 2b-stage nano-sized liver cell targeting system that can be added very simply to any form of commercially available insulin. Diasome’s Hepatocyte Directed Vesicles (HDV) liver targeting system is designed to minimize hypoglycemia by enabling the body’s natural glucose metabolism mechanism, based in liver hepatocytes, to function more normally during insulin therapy. HDV enables more injected insulin to reach its target in the liver.
Robert Geho CEO
W. Blair Geho, MD, PhD Chief Scientific Officer
Marc S. Penn, MD, PhD Chief Medical Officer
Douglas B. Muchmore, MD Chief Technology Officer
Christine Smith, PhD Chief Manufacturing Officer
Helga Kautsky, CPA Chief Financial Officer
Kerry Watterson Corporate Development
W. Blair Geho
Marc S. Penn
Bruce Bode, MD
Jeremy Pettus, MD
Robert Henry, MD